Emily C Edmonds1, Katherine J Bangen1, Lisa Delano-Wood1, Daniel A Nation2, Ansgar J Furst3, David P Salmon4, Mark W Bondi1. 1. 1Department of Psychiatry,University of California San Diego,School of Medicine,La Jolla,California. 2. 3Department of Psychology,University of Southern California,Los Angeles,California. 3. 4War Related Illness and Injury Study Center (WRIISC),VA Palo Alto Health Care System,Palo Alto,California. 4. 6Department of Neurosciences,University of California San Diego,School of Medicine,La Jolla,California.
Abstract
OBJECTIVES: We examined florbetapir positron emission tomography (PET) amyloid scans across stages of preclinical Alzheimer's disease (AD) in cortical, allocortical, and subcortical regions. Stages were characterized using empirically defined methods. METHODS: A total of 312 cognitively normal Alzheimer's Disease Neuroimaging Initiative participants completed a neuropsychological assessment and florbetapir PET scan. Participants were classified into stages of preclinical AD using (1) a novel approach based on the number of abnormal biomarkers/cognitive markers each individual possessed, and (2) National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria. Preclinical AD groups were compared to one another and to a mild cognitive impairment (MCI) sample on florbetapir standardized uptake value ratios (SUVRs) in cortical and allocortical/subcortical regions of interest (ROIs). RESULTS: Amyloid deposition increased across stages of preclinical AD in all cortical ROIs, with SUVRs in the later stages reaching levels seen in MCI. Several subcortical areas showed a pattern of results similar to the cortical regions; however, SUVRs in the hippocampus, pallidum, and thalamus largely did not differ across stages of preclinical AD. CONCLUSIONS: Substantial amyloid accumulation in cortical areas has already occurred before one meets criteria for a clinical diagnosis. Potential explanations for the unexpected pattern of results in some allocortical/subcortical ROIs include lack of correspondence between (1) cerebrospinal fluid and florbetapir PET measures of amyloid, or between (2) subcortical florbetapir PET SUVRs and underlying neuropathology. Findings support the utility of our novel method for staging preclinical AD. By combining imaging biomarkers with detailed cognitive assessment to better characterize preclinical AD, we can advance our understanding of who is at risk for future progression. (JINS, 2016, 22, 978-990).
OBJECTIVES: We examined florbetapir positron emission tomography (PET) amyloid scans across stages of preclinical Alzheimer's disease (AD) in cortical, allocortical, and subcortical regions. Stages were characterized using empirically defined methods. METHODS: A total of 312 cognitively normal Alzheimer's Disease Neuroimaging Initiative participants completed a neuropsychological assessment and florbetapir PET scan. Participants were classified into stages of preclinical AD using (1) a novel approach based on the number of abnormal biomarkers/cognitive markers each individual possessed, and (2) National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria. Preclinical AD groups were compared to one another and to a mild cognitive impairment (MCI) sample on florbetapir standardized uptake value ratios (SUVRs) in cortical and allocortical/subcortical regions of interest (ROIs). RESULTS: Amyloid deposition increased across stages of preclinical AD in all cortical ROIs, with SUVRs in the later stages reaching levels seen in MCI. Several subcortical areas showed a pattern of results similar to the cortical regions; however, SUVRs in the hippocampus, pallidum, and thalamus largely did not differ across stages of preclinical AD. CONCLUSIONS: Substantial amyloid accumulation in cortical areas has already occurred before one meets criteria for a clinical diagnosis. Potential explanations for the unexpected pattern of results in some allocortical/subcortical ROIs include lack of correspondence between (1) cerebrospinal fluid and florbetapir PET measures of amyloid, or between (2) subcortical florbetapir PET SUVRs and underlying neuropathology. Findings support the utility of our novel method for staging preclinical AD. By combining imaging biomarkers with detailed cognitive assessment to better characterize preclinical AD, we can advance our understanding of who is at risk for future progression. (JINS, 2016, 22, 978-990).
Authors: Emily C Edmonds; Lisa Delano-Wood; Lindsay R Clark; Amy J Jak; Daniel A Nation; Carrie R McDonald; David J Libon; Rhoda Au; Douglas Galasko; David P Salmon; Mark W Bondi Journal: Alzheimers Dement Date: 2014-05-22 Impact factor: 21.566
Authors: Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun Journal: J Nucl Med Date: 2012-11-19 Impact factor: 10.057
Authors: Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky Journal: J Nucl Med Date: 2012-02-13 Impact factor: 10.057
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2009 Apr-Jun Impact factor: 2.703
Authors: Katherine J Bangen; Alexandra L Clark; Madeline Werhane; Emily C Edmonds; Daniel A Nation; Nicole Evangelista; David J Libon; Mark W Bondi; Lisa Delano-Wood Journal: J Alzheimers Dis Date: 2016-03-29 Impact factor: 4.472
Authors: Thomas G Beach; Dietmar Rudolf Thal; Michelle Zanette; Adrian Smith; Christopher Buckley Journal: J Alzheimers Dis Date: 2016-03-31 Impact factor: 4.472
Authors: Jon B Toledo; Nigel J Cairns; Xiao Da; Kewei Chen; Deborah Carter; Adam Fleisher; Erin Householder; Napatkamon Ayutyanont; Auttawut Roontiva; Robert J Bauer; Paul Eisen; Leslie M Shaw; Christos Davatzikos; Michael W Weiner; Eric M Reiman; John C Morris; John Q Trojanowski Journal: Acta Neuropathol Commun Date: 2013-10-09 Impact factor: 7.801
Authors: Shady Rahayel; Christian Bocti; Pénélope Sévigny Dupont; Maude Joannette; Marie Maxime Lavallée; Jim Nikelski; Howard Chertkow; Sven Joubert Journal: Hum Brain Mapp Date: 2019-05-30 Impact factor: 5.038
Authors: Omonigho M Bubu; Elizabeth Pirraglia; Andreia G Andrade; Ram A Sharma; Sandra Gimenez-Badia; Ogie Q Umasabor-Bubu; Megan M Hogan; Amanda M Shim; Fahad Mukhtar; Nidhi Sharma; Alfred K Mbah; Azizi A Seixas; Korey Kam; Ferdinand Zizi; Amy R Borenstein; James A Mortimer; Kevin E Kip; David Morgan; Ivana Rosenzweig; Indu Ayappa; David M Rapoport; Girardin Jean-Louis; Andrew W Varga; Ricardo S Osorio Journal: Sleep Date: 2019-06-11 Impact factor: 5.849
Authors: Edmarie Guzmán-Vélez; Sehily Jaimes; Daniel C Aguirre-Acevedo; Daniel J Norton; Kathryn V Papp; Rebecca Amariglio; Dorene Rentz; Ana Baena; Eliana Henao; Victoria Tirado; Claudia Muñoz; Margarita Giraldo; Reisa A Sperling; Francisco Lopera; Yakeel T Quiroz Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Peter N E Young; Mar Estarellas; Emma Coomans; Meera Srikrishna; Helen Beaumont; Anne Maass; Ashwin V Venkataraman; Rikki Lissaman; Daniel Jiménez; Matthew J Betts; Eimear McGlinchey; David Berron; Antoinette O'Connor; Nick C Fox; Joana B Pereira; William Jagust; Stephen F Carter; Ross W Paterson; Michael Schöll Journal: Alzheimers Res Ther Date: 2020-04-27 Impact factor: 6.982
Authors: G A Stonebarger; H F Urbanski; R L Woltjer; K L Vaughan; D K Ingram; P L Schultz; S M Calderazzo; J A Siedeman; J A Mattison; D L Rosene; S G Kohama Journal: Geroscience Date: 2020-09-02 Impact factor: 7.581
Authors: Gemma C Howdle; Yann Quidé; Mustafa S Kassem; Kate Johnson; Caroline D Rae; Bruce J Brew; Lucette A Cysique Journal: Neurol Neuroimmunol Neuroinflamm Date: 2020-05-11